FDA accepts new drug application of Mirati Therapeutics for NSCLC therapy

Mirati Therapeutics’ NDA is supported by findings from the Phase II registration-enabling cohort of the KRYSTAL-1 trial.. Credit: Mirati Therapeutics, Inc.



  • FDA